CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年3月23日～2025年3月29日の間に収集した論文情報を追加しました。

  1. Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.

  免疫チェックポイント阻害薬は急性膵炎リスクを増加

  対象DB：FAERS

  2. Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system.

  SZCは新たな副作用も示し、臨床監視が重要

  対象DB：FAERS

  3. The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles.

  シンバスタチンは筋肉障害のリスクが高い

  対象DB：FAERS

  4. Drug-associated hyperprolactinemia: a comprehensive disproportionality analysis based on the FAERS database.

  精神薬が高プロラクチン血症に関連し、年齢や性別で差異あり

  対象DB：FAERS

  5. Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.

  ETIによる副作用には精神的健康問題が含まれる

  対象DB：FAERS

  6. Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database.

  ファリシマブの副作用について、眼疾患や視力障害に加えて、いくつか新たな副作用も確認

  対象DB：FAERS

  7. Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database.

  BCR-ABL阻害薬と抗真菌薬併用で不整脈リスク増加

  対象DB：FAERS

  8. Development of a Medication-Related Osteonecrosis of the Jaw Prediction Model Using the FDA Adverse Event Reporting System Database and Machine Learning.

  MRONJ誘発薬の予測モデルを化学構造で構築

  対象DB：FAERS

  9. Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Data.

  レガデノソンの新たな副作用を特定

  対象DB：FAERS

  10. Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database.

  オランザピンは横紋筋融解症と強い関連

  対象DB：FAERS

  11. Analysis and comparison of adverse events of colistin administered by different routes based on the FAERS database.

  コリスチン静注は他経路より副作用が多い

  対象DB：FAERS

  12. Safety Profile and Hepatotoxicity of Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Disproportionality Analysis Based on FDA Adverse Event Reporting System Database.

  ALK-TKIの肝毒性を含む未報告の副作用シグナルを特定

  対象DB：FAERS

  13. Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases.

  FAERSデータを使用し、33薬剤が起立性低血圧と関連

  対象DB：FAERS,JADER

  14. Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?

  セマグルチドとNAIONの関連性について、安全性シグナルの可能性を示唆

  対象DB：FAERS

  15. Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

  薬剤間相互作用とトルサード・ド・ポアントの関係を調査

  対象DB：FAERS

  16. Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis.

  SZCの副作用に関するFAERSデータ解析結果

  対象DB：FAERS

  17. Toxicities Associated with Sacituzumab Govitecan: Data from Clinical Trials and a Real-World Pharmacovigilance Database.

  サシツズマブ・ゴビテカンの副作用と薬物相互作用

  対象DB：FAERS

  18. Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases.

  アトルバスタチンは記憶保護効果が示唆されるが、個々の副作用には注意が必要

  対象DB：FAERS

  19. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis.

  SMX-TMPは他の抗生物質と比較して副作用リスクが高い

  対象DB：FAERS

  20. Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reports (FAERS) for drug-induced sinusitis.

  薬剤誘発性副鼻腔炎とその薬理遺伝学的メカニズムの解析

  対象DB：FAERS

  21. Dasatinib-Associated Chylothorax: A Review of Cases Reported to the FDA Adverse Event Reporting System and the Published Literature.

  ダサチニブ関連乳び胸のFDA報告と文献レビュー

  対象DB：FAERS

  22. Retrospective Clinical Investigation into the Association Between Abnormal Blood Clotting, Oral Anticoagulant Therapy, and Medium-Term Mortality in a Cohort of COVID-19 Patients.

  OATはCOVID-19中期死亡率に影響なし

  対象DB：EudraVigilance

  23. Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data.

  NMVrはRDVより神経精神系副作用が多い

  対象DB：EudraVigilance

  24. Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase.

  トファシチニブとルキソリチニブで神経障害の可能性

  対象DB：VigiBase

  25. Fractures Associated with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database.

  ICI使用は骨粗鬆症や骨折と関連なし

  対象DB：VigiBase

  26. Global Burden of Vaccine-Associated Cerebrovascular Venous Sinus Thrombosis, 1968-2024: A Critical Analysis From the WHO Global Pharmacovigilance Database.

  Ad5ベクターワクチンはCVSTリスク増加

  対象DB：VigiBase

  27. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.

  JAK阻害薬は抗TNFαよりMACE報告が多い

  対象DB：VigiBase

  28. Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.

  アンピシリン・スルバクタムは死亡率が高い

  対象DB：DPC

  29. Which of vonoprazan alone or intravenous proton pump inhibitor followed by vonoprazan is optimal for reducing delayed bleeding in gastric endoscopic submucosal dissection?

  抗血栓薬使用時は静注PPI後ボノプラザンが有効

  対象DB：DPC

  30. Readmissions and costs in cadaveric and living-donor lobar lung transplantation: Analysis using a national database.

  LDLLTはCLTより再入院率と医療費が低い

  対象DB：DPC

  31. Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching-A Japanese e-Delphi Survey.

  GPP治療のバイオロジック切り替えに関する研究

  対象DB：JMDC,MDV

  32. Trends of Strong and Weak Opioid Prescriptions in Japan: A Cross-Sectional Study Based on Open Data from the National Database and Hospital Claims Data from Fiscal Years 2015 to 2021.

  日本のがん患者のオピオイド使用傾向分析

  対象DB：NDB

  33. Ethnic and Socio-Economic Variations in Comorbidity and Mortality in Cancer Survivors: A UK Population-Based Observational Study.

  英国のがん生存者における民族・社会経済状況による合併症の差と死亡リスクを調査

  対象DB：CPRD

  34. Regional variation in non-traumatic major lower limb amputation in England: observational study of linked primary and secondary care data.

  下肢切断の発生率減少も地域差存在

  対象DB：CPRD

  35. Pre-pregnancy care in general practice in England: cross-sectional observational study using administrative routine health data.

  英国での女性の妊娠前ケアが不十分で、特にリスクのある女性への支援が少ない

  対象DB：CPRD

  36. Clinical consequences of varenicline shortage: A study on the French national pharmacovigilance database.

  バレニクリン欠品により喫煙再開のリスクが確認された

  対象DB：FPVD

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み